FLT3 and acute myeloid leukemia: FLT3 tyrosine kinase inhibitors (TKI), developed as ATP-competitive inhibitors, are currently the focus of new development strategies in FLT3-mutated AML, both as single agents at relapse and in combination with intensive chemotherapy or as first-line maintenance therapy.